Clinical Trials on Spatial Neglect in Japan

Total 30 results

GlaxoSmithKline

Withdrawn

Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects

Epilepsy, Partial

Japan
SK Life Science, Inc.

Active, not recruiting

Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS

Partial Seizure | Focal Seizure

China, Japan, Korea, Republic of
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

Epilepsy | Partial Seizures With or Without Secondary Generalization

Japan
UCB Japan Co. Ltd.
Parexel

Completed

Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures

Epilepsy | Partial-onset Seizures

Japan
Eisai Co., Ltd.

Completed

An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)

Refractory Partial Seizures

Japan
Eisai Co., Ltd.

Completed

Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures (FYC01S)

Partial Seizures (With or Without Secondary Generalized Seizures) | Primary Generalized Tonic-clonic Seizures

Japan
Eisai Co., Ltd.

Completed

A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)

Refractory Partial Seizures

Japan
Eisai Co., Ltd.

Completed

Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures (FYC02T)

Partial Seizures (With or Without Secondary Generalized Seizures) | Primary Generalized Tonic-clonic Seizures

Japan
UCB Japan Co. Ltd.

Completed

A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures

Epilepsy | Partial-onset Seizures

Japan
UCB Japan Co. Ltd.

Completed

An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures

Epilepsy | Partial Onset Seizures

Japan
UCB Japan Co. Ltd.

Completed

A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age (PEACH)

Partial Seizures

Japan
Eisai Co., Ltd.

Completed

Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)

Partial Onset Seizures

Japan, Korea, Republic of
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Phase III Open-Label Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures

Epilepsies, Partial

Japan
UCB Japan Co. Ltd.

Completed

An Open Label Study of Levetiracetam in Japanese Pediatric Patients With Partial Seizures

Epilepsy | Partial Seizures

Japan
UCB Japan Co. Ltd.

Completed

An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy

Epilepsy | Partial Onset Seizures

Japan
UCB Biopharma SRL

Enrolling by invitation

A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

Epilepsy | Partial Seizures With or Without Secondary Generalization

China, Japan
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures

Partial Onset Seizures

Japan
Nobelpharma

Completed

Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures

Partial Onset Seizures

Japan
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures

Epilepsies, Partial

Japan
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy

Epilepsy | Partial Seizures With or Without Secondary Generalization

China, Japan, Malaysia, Philippines, Singapore, Taiwan, Thailand
UCB Japan Co. Ltd.

Completed

A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset Seizures

Epilepsies, Partial

Japan
UCB Pharma SA
UCB Japan Co. Ltd.

Completed

Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures

Epilepsy | Partial-onset Seizures

China, Japan
Eisai Co., Ltd.

Completed

A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

Partial-onset Seizures

Korea, Republic of, Japan, Australia, China, Malaysia, Taiwan, Thailand
UCB Pharma SA
UCB Japan Co. Ltd.

Completed

A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures

Epilepsy | Partial Onset Seizures

China, Japan
UCB Japan Co. Ltd.

Completed

A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures

Epilepsies | Partial

Japan
Eisai Inc.

Completed

Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

Partial-Onset or Primary Generalized Tonic-Clonic Seizures

Canada, France, Italy, Korea, Republic of, Spain, United States, Belgium, Czechia, Hungary, Japan, Latvia, Poland
Hoffmann-La Roche
Chugai Pharmaceutical Co.

Recruiting

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis (Cielo)

NMDAR Autoimmune Encephalitis | LGI1 Autoimmune Encephalitis

United States, Korea, Republic of, China, Japan, Czechia, Italy, Poland, Austria, Brazil, Argentina, Netherlands, Taiwan, France, Denmark, Ghana
AstraZeneca
Merck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaborators

Active, not recruiting

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Relapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA Mutated

Korea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain
AstraZeneca
Merck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Advanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum Chemotherapy

Korea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain
ppharmaand GmbH
Bristol-Myers Squibb; Gynecologic Oncology Group; European Network of Gynaecological... and other collaborators

Active, not recruiting

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response

United States, United Kingdom, Korea, Republic of, Russian Federation, Canada, Denmark, Taiwan, New Zealand, Ireland, Japan, Spain, Australia, Israel, Italy, Greece, Sweden, Czechia, Finland, Poland, Belgium, Germany, Romania, Singa... and more

3

Subscribe